Compare Abbott Laboratories (ABT) vs Mattel Inc (MAT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Mattel Inc — how do they compare? Abbott Laboratories trades at $95.48 (market cap $166.94B), while Mattel Inc trades at $13.14 (market cap $3.90B). The key difference: Abbott Laboratories is far larger — about 42.8× Mattel Inc's market cap, and Abbott Laboratories pays a 2.63% dividend while Mattel Inc pays none. Which is the better fit depends on your goals.
| ABT | MAT | |
|---|---|---|
Market Cap | $166.94B | $3.90B |
Sector | Health | Consumer Cyclical |
52-Week High | $136.62 | $22.16 |
52-Week Low | $82.57 | $13.05 |
Enterprise Value | $193.69B | $5.71B |
Dividend Yield | 2.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
Mattel (MAT) trades at $13.42, up 0.6% on the day, with a bearish technical signal but bullish oscillators like RSI suggesting potential oversold conditions. The company reported mixed recent earnings, missing in Q3 and Q4 2025 but beating in Q1 2026, with Q2 2026 results pending. Financially, it maintains solid profitability with a 9.27% net margin and attractive valuation ratios, including a P/E of 8.36. Recent news highlights brand expansions and a shareholder push for strategic alternatives.
The outlook is cautiously optimistic, supported by strong brand portfolio and analyst consensus, but risks include declining cash flows and competitive pressures. Investment opportunities lie in potential strategic moves and undervaluation, while key risks involve execution challenges and market sentiment shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Mattel Inc
Mattel markets toy products that are sold to its wholesale customers and direct to retail consumers. The company offers products for children and families, including toys for infants and preschoolers, girls and boys, youth electronics, handheld and other games, puzzles, educational toys, media-driven products, and plush and fashion-related toys. Mattel's owned portfolio includes Barbie, Hot Wheels, Fisher-Price, Thomas & Friends, and American Girl. In addition, it currently manufactures toy products for its segments both internally and externally (through manufacturing partners). Just over half of its net sales are in North America, while the remainder stem from international markets.
Read more on MAT →
